Johnson & Johnson’s (J&J) blockbuster cancer immunotherapy, Darzalex (daratumumab), has secured European approval for self-administration, marking the first time an oncology injectable has achieved this milestone on the continent. Through this Type II label change, approved by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP), Darzalex will now become available to European patients for either patient or caregiver administration after the fifth dose, provided the u ...

Key Takeaways J&J's Innovative Medicine unit is expected to post Q1 growth despite Stelara LOE impactJNJ's growth likely driven by Darzalex, Tremfya, Erleada and the uptake of newer therapies like CarvyktiJNJ faces pressure from Stelara biosimilars, Imbruvica decline and Part D redesign headwindsJohnson & Johnson (JNJ) , via its Innovative Medicine segment, markets a broad portfolio of blockbuster therapies across key areas including neuroscience, cardiovascular and metabolic diseases, immunology, oncology, ...

Landmark decision by CHMP grants approval for self or caregiver administration for patients living with multiple myeloma1 Milestone is a testament to ten years of daratumumab experience and innovation, continuing to transform multiple myeloma care BEERSE, BELGIUM, March 27, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted approval for a Type II variation to the labelling for DARZALEX® ...

An updated edition of the February 5, 2026, article.The global oncology market is entering a period of rapid evolution, fueled by rising cancer incidence, aging populations and continued scientific breakthroughs. According to the American Cancer Society, the United States alone is projected to record approximately 2.1 million new cancer cases and more than 626,000 deaths in 2026. On a global scale, increasing exposure to lifestyle-related risk factors—such as smoking, obesity, and sedentary behavior— and de ...

Key Takeaways J&J advanced its pipeline in 2025 with key approvals across oncology and immunologyJNJ secured approvals for Inlexzoh, Imaavy and Icotyde, expanding treatment options and pipeline depthJNJ's new cancer drugs generated $3B in 2025, with more growth expected from launches in 2026Johnson & Johnson (JNJ) has a strong R&D pipeline, with primary focus areas being immunology, oncology and neuroscience. J&J rapidly advanced its pipeline in 2025, attaining significant clinical and regulatory milestones ...

Johnson & Johnson ( JNJ ) is a true Dividend King with more than 60 years of consecutive dividend growth. In this uncertain market, investing in a dividend juggernaut with above-inflation long-term growth is just the medicineI have been an investor for a number of years mainly focusing on dividend paying companies. I think dividends and, perhaps more importantly, the growth of them, are foundational for high risk-adjusted long term returns. My approach is therefore to focus on stocks that either pay stable ...

The Dow Jones Industrial Average (^DJI) was up 305.43 (+0.66%) points today, closing at 46,429.49. Dow Futures (YM=F) also signaled strength, rising 280.00 (+0.60%) points to reach 46,695.00. The primary driver for Wednesday’s market action was a better-than-expected Durable Goods report, which suggested that capital spending remains resilient despite elevated borrowing costs. This economic data sparked a rally in cyclical stocks, as investors gained confidence in a "soft landing" scenario for the U.S. econ ...

Johnson & Johnson (NYSE:JNJ) is included in our list of the 11 most overvalued companies according to the media. Punitive Damages Award Worth $950 Million Overturned Against Johnson & Johnson (JNJ), $16M Talc Verdict Stands Trong Nguyen / Shutterstock.com Regarding a mesothelioma case, where a woman allegedly died from ‌cancer caused by the company’s talc products, Johnson & Johnson (NYSE:JNJ) faced a setback on March 16, 2026. That day, a California judge upheld $16 million in compensatory damages for ...

Turning 65 with $1 million saved puts you in a position most Americans will likely never reach, but hitting this number is only half the work. The more important question is what that $1 million actually produces every month for the next 25 to 30 years, and whether that income will keep pace with a life that keeps getting more expensive. Quick Read A $1 million portfolio at 65 generates $2,917 to $5,833 monthly depending on yield strategy, with conservative 3-4% yields producing roughly $2,917, balance ...

Key TakeawaysThe U.S. has delivered a 15-point ceasefire proposal to Iran via Pakistani officials, including provisions for sanctions relief, a nuclear rollback, and guaranteed access to the Strait of Hormuz.BlackRock (BLK) CEO Larry Fink warned that a spike in oil prices to $150 per barrel would trigger a global recession, as energy costs continue to pressure European economies.European equity markets rallied on hopes of a diplomatic breakthrough, with Germany’s DAX rising 1.5% and the STOXX 600 gaining 0. ...